Orata Dosage/Direction for Use

Administer on an empty stomach once daily.
Nucleoside treatment naive: initial 0.5 mg once daily.
Lamivudine refractory (eg. Evidence of viraemia while on lamivudine or the presence of lamivudine resistance mutations that known as YMDD gene): initial 1 mg once daily. Taken on an empty stomach (more than 2 hours before or more than 2 hours after a meal).
Renal impairment: Entecavir is predominantly eliminated by the kidney. The clearance of entecavir decreases with impaired creatinine clearance. Dose adjustment is recommended for patients who have creatinine clearance <50 mL/min including those on hemodialysis or continuous ambulatory peritoneal dialysis (CAPD) as shown in table. (See table.)

Click on icon to see table/diagram/image

Hepatic impairment: No dosage adjustment necessary.
Pediatric and adolescent: The safety and efficacy in patients <16 years of age have not been established.
Geriatric: No dosage adjustment based on age is required.
Treatment duration: The optimal duration of treatment for patients with chronic hepatitis B infection and the relationship between treatment and long-term outcomes eg, cirrhosis and hepatocellular carcinoma are unknown.